Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating ...

The Phase 2 FOURLIGHT-1 trial shows that atirmociclib plus fulvestrant significantly improves progression-free survival in HR+, HER2- metastatic breast cancer after CDK4/6 inhibitors, reducing ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination ...

Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that the first patient ...

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

Novartis has struck a front-loaded deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion, ...

Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 ...

Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.

Dr. Hope Rugo and advocate Jonise Louis discuss new ADCs, biomarker testing, and patient-centered dosing for metastatic triple-negative breast cancer. The treatment paradigm for metastatic ...

Pfizer on Tuesday said the randomized Phase 2 study met its primary endpoint, showing a 40% reduction in the risk of disease progression or death with a manageable safety profile.

ELV001 aiming to disrupt the treatment paradigm for patients with incomplete response to standard of care (methotrexate + TNF inhibitors)Phase 2b ...